Change in diuretic dose after administration of Tolvaptan in liver cirrhosis patients with ascites

Change in diuretic dose after administration of Tolvaptan in liver cirrhosis patients with ascites - Change in diuretic dose in liver cirrhosis patients with ascites

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038304

Enrollment

100

Registered

2019-10-20

Start date

2019-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with liver cirrohsis with ascites in hepatic edema. Diagnosis of liver cirrhosis was based on laboratory results and imaging tests 2)Patients given oral furosemide 40-100mg/day and Spironolactone 25mg-200mg at the time of enrolling.

Exclusion criteria

Exclusion criteria: 1)The anuric patients 2)Patients with urinary retention 3)Serum Na >=147mEq/L

Design outcomes

Primary

Measure	Time frame
To assess the rate of patients who attain furosemide free and tolvaptan free.	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University school of medicine Department of Gastroenterology

kiruha555@yahoo.co.jp+81-42-778-8111

Outcome results